- Hepatitis C Virus Cases Nearly Triple in 5 years
READ NEWS - Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies
READ NEWS - Hepatitis Tied to Parkinson’s Risk
READ NEWS - Cirrhosis Increasing Among Hepatitis C Patients, According to Large US Study
READ NEWS - Hepatitis C – Hepatitis Central.Com
READ NEWS - Primary care providers can effectively treat people with hepatitis C
READ NEWS - VA Study Confirms High Cure Rates With Use Of New Hepatitis C Drugs
READ NEWS - Hepatitis C virus and neurological damage
READ NEWS - Over 1 million treated with highly effective hepatitis C medicines
READ NEWS - Gilead and Massachusetts Agree to Rebates for Hep C Drugs
READ NEWS - FDA approves Epclusa
READ NEWS - Hepatitis C Antibody Screening in a Retail Pharmacy Setting: Local Testing and Linkage to Care via an HCV Management Specialist
READ NEWS - Covering Costly HCV Tx: Who Makes that Call?
READ NEWS - CDC Press Release: Hepatitis C Kills More Americans Than Any Other Infectious Disease
READ NEWS - HCV Testing: CDC Recommendations Miss 25% of Infections
READ NEWS - Merck's Zepatier shows high response rates in hep C trials
READ NEWS - New hepatitis C regimen shows high cure rates: studies
READ NEWS - Nearly one-third of patients with previous HCC recur after DAA therapy
READ NEWS - FDA Approves Merck’s New Hepatitis C Treatment
READ NEWS - AASLD 2015: High Cure Rate for People Retreated After Failure of Short Course DAA Therapy
READ NEWS - AASLD 2015: Clinical Impact of DAAS -- Referrals for Liver Transplants Drop
READ NEWS - AASLD 2015: Daclatasvir + Sofosbuvir with Ribavirin Cures 90% of Genotype 3 Hepatitis C Patients
READ NEWS - AASLD 2015: Almost Half of U.S. Medicaid Recipients Denied Funding for Hepatitis C Treatment
READ NEWS - Large Cure Rate for Patients with Hepatitis C May Have a Significant Impact on the Transplant Wait List
READ NEWS - Nearly Half of Hepatitis C Patients on Medicaid Denied Coverage for Life-Saving Drugs, Penn Researchers Report
READ NEWS - ALLY 3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin Demonstrates High Cure Rates in Chronic Hepatitis C Genotype 3 Patients with Advanced Fibrosis or Cirrhosis
READ NEWS - The Risk of Developing Liver Cancer Even After Being Cured from Hepatitis C
READ NEWS - Early HCV fibrosis suggests need for early treatment
READ NEWS - Grazoprevir-elbasvir effective for hepatitis C in advanced chronic kidney disease
READ NEWS - Gilead's Hepatitis C Drug Works Against All Strains in Trial
READ NEWS - Therapy Respond Well to AbbVie Hepatitis C Treatment
READ NEWS - White House Under Pressure To Promote Better Access For Hepatitis C Drugs
READ NEWS
-
EASL – European Association for the Study of Liver Disease
Amsterdam, Netherlands
April 19, 2017 - April 23, 2017
http://www.easl.eu/discover/events/international-liver-congress -
DIGESTIVE DISEASE WEEK
May 6, 2017 - May 9, 2017
Chicago, IL
http://www.ddw.org/home -
HCV 2017
September 25 – 28, 2017
4th International Symposium
Hyannas, MA
http://www.hcv2017.org/ -
AASLD – The Liver Meeting 2017
October 20 – 24, 2017
Washington, DC
http://www.aasld.org/events-professional-development/liver-meeting
This site complies with the HONcode standard for trustworthy health information:
verify here.
The information provided on this site is intended to support, not replace, the relationship that exists between a patient and his/her physician. Hepatitis C Association does not display commercial content or receive funding from advertising products or services.
Support line: 877-HELP-4-HEP (877-435-7443)
For questions about Harvoni or Sovaldi providers & patients call 1-855-769-7284
Or visit the following websites:
Patient Advocate Foundation call 1-800-532-5274 or visit www.patientadvocate.org
For Questions about Viekira Pak
Call 1-844-2-PROCEED (1-844-277-6233)
or visit www.viekira.com
For questions about Olysio
Call 1-855-65-99747 or visit www.olysio.com
